Orchestra BioMed Holdings (OBIO) Operating Leases (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Operating Leases for 5 consecutive years, with $730000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 51.85% year-over-year to $730000.0; the TTM figure through Mar 2026 stood at $730000.0 (down 51.85% YoY), while the FY2025 annual figure was $936000.0, down 44.52% from the prior year.
• Operating Leases eased to $730000.0 in Q1 2026 per OBIO's latest filing, from $936000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $1.7 million in Q4 2024 and bottomed at $730000.0 in Q1 2026.
• Historically, Operating Leases has averaged $1.3 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases surged 62.52% — and 2026, when it sank 51.85%.
• Orchestra BioMed Holdings' Operating Leases stood at $1.7 million in 2022, then tumbled by 38.32% to $1.0 million in 2023, then soared by 62.52% to $1.7 million in 2024, then plunged by 44.52% to $936000.0 in 2025, then decreased by 22.01% to $730000.0 in 2026.
• Business Quant data shows OBIO's Operating Leases at $730000.0 in Q1 2026, $936000.0 in Q4 2025, and $1.1 million in Q3 2025.